MedPage Today on MSN

Compounded Imiquimod Shows Promise for Ocular Surface Cancers

A compounded form of imiquimod, a topical immune response modifier, showed promise as a treatment for ocular surface ...
Healio

FDA approves durvalumab regimen for resectable gastric, gastroesophageal cancers

The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as neoadjuvant and ...

Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight

The treatment strategy may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, each aimed at slowing disease progression and, in many cases, temporarily reducing the ...
Targeted Oncology

November 2025: Key FDA Highlights in Oncology

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...
PMLive

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult ...
Oncology Nursing News

What Oncology Therapies Were Approved by the FDA in November?

The FDA approved the combination of durvalumab (Imfinzi) plus FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and ...